| Literature DB >> 30180202 |
Camilo Germán Alberto Pérez Chaparro1, Philipp Zech2, Felipe Schuch3, Bernd Wolfarth4, Michael Rapp2, Andreas Heiβel2.
Abstract
BACKGROUND: Infection with human immunodeficiency virus (HIV) affects muscle mass, altering independent activities of people living with HIV (PLWH). Resistance training alone (RT) or combined with aerobic exercise (AE) is linked to improved muscle mass and strength maintenance in PLWH. These exercise benefits have been the focus of different meta-analyses, although only a limited number of studies have been identified up to the year 2013/4. An up-to-date systematic review and meta-analysis concerning the effect of RT alone or combined with AE on strength parameters and hormones is of high value, since more and recent studies dealing with these types of exercise in PLWH have been published.Entities:
Mesh:
Year: 2018 PMID: 30180202 PMCID: PMC6122835 DOI: 10.1371/journal.pone.0203384
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Systematic search strategy.
| Database | Combined MeSH terms and text words |
|---|---|
| PubMed | (HIV) OR (human immunodeficiency virus) AND (exercise OR exercise therapy OR physical activity OR aerobic exercise OR resistance training) AND (hormone OR testosterone OR cardiovascular OR strength OR fitness OR physiological) AND (randomized controlled trial OR randomized OR clinical trials) |
| Cochrane library | ("HIV" OR "human immunodeficiency virus") AND ("exercise" OR "physical activity" OR "aerobic exercise" OR "resistance training" OR "exercise therapy") AND ("hormone" OR "testosterone" OR "cardiovascular" OR "strength" OR "fitness" OR "physiological" AND "randomized controlled trial") |
| Clinicaltrials.gov | (HIV infection HIV AND exercise AND physiologic OR muscle) and (HIV AND exercise AND cardiovascular) |
| PEDro physiotherapy evidence database | (HIV exercise muscle) or (HIV exercise cardiovascular) or (HIV exercise hormones) |
| Web of Science | (HIV AND exercise) |
PEDro scale, quality assessment of included trials in the systematic review.
| Study | EC | I | II | III | IV | V | VI | VII | VIII | IX | X | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Agin D. 2001 | Y | ✓ | ✓ | ✓ | 0 | 0 | 0 | 0 | 0 | ✓ | ✓ | 5 |
| Bhasin S. 2000 | Y | ✓ | 0 | ✓ | 0 | 0 | ✓ | 0 | ✓ | ✓ | ✓ | 6 |
| Dolan S. 2006 | Y | ✓ | 0 | ✓ | 0 | 0 | 0 | ✓ | ✓ | ✓ | ✓ | 6 |
| Dudgeon WD. 2012 | Y | ✓ | 0 | ✓ | 0 | 0 | 0 | 0 | 0 | 0 | ✓ | 3 |
| Farinatti PT. 2010 | Y | ✓ | 0 | ✓ | 0 | 0 | ✓ | ✓ | ✓ | ✓ | ✓ | 7 |
| Fitch K. 2012 | Y | ✓ | 0 | ✓ | 0 | 0 | ✓ | 0 | ✓ | ✓ | ✓ | 6 |
| Grinspoon S. 2000 | Y | ✓ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ✓ | ✓ | 3 |
| Lox CL. 1995 | Y | ✓ | 0 | 0 | 0 | 0 | 0 | ✓ | 0 | ✓ | ✓ | 4 |
| Lox CL. 1996 | Y | ✓ | 0 | 0 | 0 | 0 | 0 | ✓ | 0 | ✓ | ✓ | 4 |
| Mendes EL. 2013 | Y | ✓ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ✓ | ✓ | 3 |
| Pérez-Moreno F. 2007 | Y | ✓ | ✓ | ✓ | 0 | 0 | ✓ | 0 | 0 | ✓ | ✓ | 6 |
| Shah KN. 2016 | Y | ✓ | ✓ | ✓ | 0 | 0 | ✓ | ✓ | 0 | ✓ | ✓ | 7 |
| Zanetti HR. 2016 | Y | ✓ | 0 | ✓ | 0 | 0 | 0 | ✓ | 0 | ✓ | ✓ | 5 |
EC, eligibility criteria; I: allocated randomization of subjects to groups; II: concealed allocation; III: similarities of groups at baseline; IV: blinding of subjects; V: blinding of researchers/evaluators; VI: blinding of assessors; VII: measure of at least one key outcome obtained from more than 85% of subjects initially allocated to groups; VIII: intention to treat; IX: comparison results between groups; X: measured at least one key outcome at two time points; ✓, criterion is present otherwise; 0, criterion is missing.
Fig 1Search and selection of studies from the systematic review according to PRISMA.
Physiotherapy Evidence Database (PEDro), Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA).
Fig 2Upper body strength changes after exercise in PLWH.
Standard deviation (SD), total (n participants), 95% confidence interval (95% CI), Z-score (Z), significance (p).
Fig 3Lower body strength changes after exercise in PLWH.
Standard deviation (SD), total (n participants), 95% confidence interval (95% CI), Z-score (Z), significance (p).
Body strength changes from baseline in PLWH.
| Category | Change (kg) | Overall effect | Heterogeneity | ||
|---|---|---|---|---|---|
| WMD | 95% CI | Z ( | I2 | ||
| Chest press | 10 (284) | 21.5 | 13.7–29.2 | 5.4 (< 0.00001) | 98% |
| Biceps curl | 4 (90) | 6.7 | -0.6–13.9 | 1.8 (0.07) | 95% |
| | |||||
| Chest press | 3 (86) | 16.4 | 4.8–28.1 | 2.8 (0.0006) | 95% |
| Biceps curl | 2 (68) | 9.9 | 3.1–16.7 | 2.9 (0.004) | 91% |
| | |||||
| Chest press | 6 (162) | 24.2 | 11.9–36.5 | 3.8 (< 0.0001) | 98% |
| | |||||
| Chest press | 5 (160) | 25.9 | 16.8–35.1 | 5.5 (< 0.00001) | 96% |
| Biceps curl | 2 (70) | 3.4 | -2.8–9.5 | 1.1 (0.29) | 90% |
| | |||||
| Chest press | 4 (102) | 18.9 | 17.2–20.7 | 21 (< 0.00001) | 99% |
| | |||||
| Chest press | 7 (190) | 17.9 | 10.5–25.3 | 4.8 (< 0.00001) | 96% |
| | |||||
| Chest press | 8 (238) | 25 | 16.3–33.7 | 5.6 (< 0.00001) | 98% |
| Biceps curl | 4 (90) | 6.7 | -0.6–13.9 | 1.8 (0.07) | 95% |
| | |||||
| Chest press | 4 (145) | 28.8 | 15.8–41.9 | 4.3 (< 0.00001) | 98% |
| Leg press | 7 (192) | 31.7 | 21.1–42.3 | 5.9 (< 0.00001) | 97% |
| Leg flexion | 9 (289) | 9.9 | 5.5–14.2 | 4.5 (< 0.00001) | 95% |
| Leg extension | 8 (255) | 14.9 | 6.1–23.7 | 3.3 (0.0002) | 93% |
| | |||||
| Leg press | 2 (69) | 46.1 | -27.7–119.9 | 1.2 (0.22) | 92% |
| Leg flexion | 3 (89) | 10.3 | 5.5–15 | 4.2 (< 0.0001) | 83% |
| Leg extension | 3 (89) | 20.9 | 16.7–25 | 9.9 (< 0.00001) | 19% |
| | |||||
| Leg press | 4 (101) | 41.1 | 19.1–63.1 | 3.6 (0.0003) | 98% |
| Leg flexion | 6 (191) | 13.5 | 7.4–19.7 | 4.3 (<0.0001) | 96% |
| Leg extension | 5 (157) | 18.7 | 6.3–31.2 | 2.9 (0.003) | 94% |
| | |||||
| Leg press | 3 (96) | 11.6 | 5.4–17.8 | 3.7 (0.0002) | 87% |
| Leg flexion | 6 (216) | 6.2 | 1.7–10.7 | 2.7 (0.007) | 93% |
| Leg extension | 7 (235) | 14.4 | 4.2–24.5 | 2.8 (<0.00001) | 93% |
| | |||||
| Leg press | 3 (75) | 47 | 25.2–68.9 | 4.2 (< 0.0001) | 95% |
| Leg flexion | 3 (73) | 16.7 | 4.4–29 | 2.7 (0.008) | 96% |
| | |||||
| Leg press | 4 (93) | 35.3 | 9–61.7 | 2.6 (0.009) | 98% |
| Leg flexion | 4 (109) | 8.5 | 4.5–12.4 | 4.2 (< 0.0001) | 80% |
| Leg extension | 4 (105) | 18 | 7.5–28.6 | 3.3 (< 0.0008) | 77% |
| | |||||
| Leg press | 6 (149) | 29.9 | 18.5–41.4 | 5.1 (< 0.00001) | 97% |
| Leg flexion | 9 (289) | 9.9 | 5.5–14.2 | 4.5 (< 0.00001) | 95% |
| Leg extension | 8 (255) | 14.9 | 6.1–23.7 | 3.3 (0.0009) | 93% |
| | |||||
| Leg press | 3 (105) | 15.8 | 7.4–24 | 3.7 (0.0002) | 96% |
| Leg flexion | 5 (203) | 8.8 | 2.6–15 | 2.8 (0.006) | 96% |
| Leg extension | 4 (173) | 15.7 | 1.1–30.3 | 2.1 (0.03) | 96% |
Subgroup analyses are presented in random effect model. Panel includes n trials (n participants), weighted mean difference (WMD), 95% confidence interval (95% CI), Z-score (Z) and significance (p) of exercise vs. control conditions. Statistical heterogeneity (I2). AERT = aerobic exercise combined with resistance training, RT = resistance training, ART = antiretroviral therapy. Not able to calculate (NA)
Hormone changes from baseline in PLWH.
| Category | Change | Overall effect | Heterogeneity | ||
|---|---|---|---|---|---|
| WMD | 95% CI | Z ( | I2 | ||
| Testosterone (ng/dl) | 2 (45) | 40.8 | -20.8–102.5 | 1.3 (0.19) | 0% |
| Free testosterone (pg/dl) | 3 (73) | -3 | -8–2.1 | 1.1 (0.25) | 0% |
| AERT | 2 (50) | -3.4 | -8.8–2 | 1.2 (0.21) | 0% |
| Professional supervision | 2 (51) | 0 | -11.4–11.5 | 0 (0.99) | 0% |
| IL-6 (pg/ml) | 2 (58) | -2.4 | -2.6, -2.1 | 18.6 (< 0.00001) | 0% |
| Only passive controls | 2 (58) | -2.4 | -2.6, -2.1 | 18.6 (< 0.00001) | 0% |
| IL-1β (pg/ml) | 2 (58) | -0.2 | -3–2.6 | 0.1 (0.88) | 71% |
| Only passive controls | 2 (58) | -0.2 | -3–2.6 | 0.1 (0.88) | 71% |
Subgroup analyses are presented in random effect model. Panel includes n trials (n participants), Weighted mean difference (WMD), 95% confidence interval (95% CI), Z-score (Z) and significance (p) of exercise vs. control conditions. Statistical heterogeneity (I2). AERT = aerobic exercise combined with resistance training, IL = interleukin. Not able to calculate (NA)
Sub-group differences.
| Category | Change (kg) | Overall effect | Heterogeneity | Difference | |||
|---|---|---|---|---|---|---|---|
| WMD | 95% CI | Z ( | I2 | χ2 | ( | ||
| Comorbidities | |||||||
| CP with | 4 (110) | 22.2 | 11.7–32.8 | 4.12 (< 0.0001) | 96% | 0.02 | 0.88 |
| CP without | 6 (174) | 21 | 9–32.9 | 3.4 (0.0006) | 98% | ||
| BC with | 1 (22) | 0.2 | -2.6–3 | 0.14 (0.89) | NA | 6.8 | 0.009 |
| BC without | 2 (90) | 9.9 | 3.1–16.7 | 2.9 (0.004) | 91% | ||
| LP with | 2 (44) | 68.5 | 56.7–80.3 | 11.39 (< 0.00001) | 0% | 36.7 | <0.00001 |
| LP without | 5 (148) | 22.3 | 13.1–31.5 | 4.77 (< 0.00001) | 96% | ||
| LF with | 5 (163) | 9.4 | 3.4–15.4 | 3.1 (0.002) | 94% | 0.06 | 0.81 |
| LF without | 4 (126) | 10.5 | 3.9–17.1 | 3.11 (0.002) | 94% | ||
| LE with | 5 (159) | 5.2 | 2.9–7.5 | 4.4 (<0.00001) | 92% | 44.5 | <0.00001 |
| LE without | 3 (96) | 19.3 | 15.8–22.7 | 11 (<0.00001) | 62% | ||
| Gender | |||||||
| CP women | 2 (61) | 11.2 | 6.4–16.1 | 4.5 (<0.00001) | 75% | 4 | 0.14 |
| CP mixed | 2 (52) | 32.3 | 2.6–62 | 2.1 (0.03) | 97% | ||
| CP males | 5 (129) | 20.9 | 9.6–32.3 | 3.6 (0.0003) | 97% | ||
| BC women | 1 (20) | 13.4 | 10.3–16.5 | 8 (< 0.00001) | NA | 38.5 | <0.00001 |
| BC males | 1 (22) | 0.2 | -2.6–3 | 0.1 (0.89) | NA | ||
| LP mixed | 2 (31) | 53.6 | -3.7–110.8 | 4.4 (<0.0001) | 86% | 0.3 | 0.57 |
| LP male | 4 (93) | 35.4 | 9–61.7 | 2.6 (0.009) | 98 | ||
| LF women | 2 (58) | 7.9 | 6.4–9.4 | 10.3 (<0.00001) | 0% | 1.2 | 0.55 |
| LF mixed | 3 (110) | 18.7 | -1.5–39 | 1.8 (0.07) | 98% | ||
| LF male | 3 (73) | 6.3 | -4.3–16.9 | 1.2 (0.25) | 91% | ||
| LE women | 2 (58) | 25 | 11.5–38.4 | 3.6 (0.0003) | 85% | 17.9 | 0.0001 |
| LE mixed | 2 (80) | 16.1 | -11.8–43.9 | 1.1 (0.26) | 90% | ||
| LE male | 3 (69) | 1.4 | -4.3–7.2 | 0.5 (0.62) | 0% | ||
| Type of training | |||||||
| CP AE | 1 (22) | 4 | -0.5–8.4 | 1.8 (0.08) | NA | 20 | <0.0001 |
| CP AERT | 5 (160) | 25.9 | 16.8–35.1 | 5.5 (<0.00001) | 96% | ||
| CP RT | 4 (102) | 20.4 | 4.5–36.3 | 2.5 (0.01) | 99% | ||
| BC AERT | 2 (70) | 3.4 | -2.8–9.5 | 1.1 (0.29) | 90% | 8.1 | 0.004 |
| BC RT | 1 (20) | 13.4 | 10.3–16.5 | 8.5 (<0.00001) | NA | ||
| LP AE | 1 (21) | 19.5 | 9.7–29.3 | 3.9 (<0.0001) | NA | 10.1 | 0.006 |
| LP AERT | 3 (96) | 11.6 | 5.4–17.8 | 3.7 (0.0002) | 87% | ||
| LP RT | 3 (75) | 47 | 25.2–68.9 | 4.2 (<0.0001) | 95% | ||
| LF AERT | 6 (216) | 6.2 | 1.7–10.7 | 2.7 (0.007) | 93% | 2.5 | 0.12 |
| LF RT | 3 (73) | 16.7 | 4.4–29 | 2.7 (0.008) | 96% | ||
| LE AERT | 7 (235) | 14.4 | 4.2. 24.5 | 2.8 (0.006) | 93% | 0.6 | 0.4 |
| LE RT | 1 (20) | 18.7 | 13.8–23.4 | 7.6 (<0.00001) | NA | ||
| Strength training intensity | |||||||
| CP 50–90% | 6 (175) | 14.8 | 9.7–19.8 | 5.7 (<0.00001) | 92% | 21 | <0.00001 |
| CP unknow | 3 (87) | 40.9 | 30.9–50.9 | 5.7 (<0.00001) | 91% | ||
| LP 50–90% | 5 (141) | 35.7 | 22.3–49.2 | 5.2 (<0.00001) | 97% | 1.1 | 0.29 |
| LP unknow | 1 (30) | 28.l | 23.4–32.8 | 11.7 (<0.00001) | NA | ||
| LF 50–90% | 6 (172) | 9.4 | 5.9–12.9 | 5.2 (p<0.00001) | 86% | 0.1 | 0.76 |
| LF unknow | 2 (89) | 13.1 | -10.6–15.5 | 1.1 (0.28) | 99% | ||
| LE 50–90% | 5 (149) | 19.9 | 9.3–30.4 | 3.7 (0.0002) | 91% | 9.1 | 0.003 |
| LE unknow | 2 (87) | 3.2 | 0.7–5.8 | 2.5 (0.01) | 0% | ||
| Weekly volume sessions | |||||||
| CP < 5 | 1 (34) | 31.2 | 25.8–36.6 | 11.3 (<0.00001) | NA | 18.4 | 0.0001 |
| CP 5–9 | 6 (166) | 20.6 | 19.2–22 | 28.9 (<0.00001) | 98% | ||
| CP > 10 | 2 (62) | 18.2 | 15.7–20.7 | 14.4 (<0.00001) | 99% | ||
| LF < 5 | 1 (28) | 0.04 | -6.9–7 | 0.01 (0.99) | NA | 8.5 | 0.01 |
| LF 5–9 | 6 (162) | 13.7 | 7.6–19.7 | 4.4 (<0.00001) | 94% | ||
| LF > 10 | 1 (38) | 8.7 | 6.7–15.4 | 5 (<0.00001) | NA | ||
| LE < 5 | 1 (28) | 4.6 | -9.7–18.9 | 0.6 (0.53) | NA | 2.6 | 0.28 |
| LE 5–9 | 4 (101) | 16.7 | 5.4–28 | 2.9 (0.004) | 91% | ||
| LE > 10 | 2 (57) | 22.9 | 1.9–43.9 | 2.1 (0.03) | 79% | ||
| Minutes week | |||||||
| CP 180 | 4 (90) | 9 | 4.9–13.2 | 4.3 (<0.0001) | 64% | 15.2 | 0.0005 |
| CP 240–270 | 3 (109) | 32.8 | 21.4–44.3 | 5.6 (<0.00001) | 95% | ||
| CP 360 | 1 (39) | 13.5 | 10.8–16.2 | 9.8 (<0.00001) | NA | ||
| BC 180 | 2 (42) | 6.1 | 4.1–8.2 | 5.8 (<0.00001) | 97% | 0.04 | 0.84 |
| BC 240 | 1 (48) | 6.5 | 3.8–9.2 | 4.7 (<0.00001) | NA | ||
| LP 180 | 3 (64) | 44.5 | 17.6–71.4 | 3.2 (0.001) | 91% | 6.2 | 0.01 |
| LP 240–270 | 2 (75) | 10.2 | 7.3–13.1 | 6.9 (<0.00001) | 68% | ||
| LF 180 | 3 (63) | 9.5 | 1.3–17.7 | 2.2 (0.02) | 90% | 0.7 | 0.71 |
| LF 240 | 2 (78) | 5.1 | -3.5–13.7 | 1.2 (0.24) | 82% | ||
| LF 360 | 1 (38) | 8.7 | 6.5–10.9 | 7.8 (<0.00001) | NA | ||
| LE 180 | 3 (63) | 15.1 | -1.1–31.5 | 1.8 (0.07) | 92% | 7 | 0.03 |
| LE 240–270 | 3 (95) | 14.1 | 2.1–26.2 | 2.3 (0.02) | 67% | ||
| LE 360 | 1 (38) | 32.4 | 23.3–41.5 | 7 (<0.00001) | NA | ||
| Strength test | |||||||
| CP 1-RM | 6 (181) | 20.9 | 11.3–30.4 | 4.3 (<0.0001) | 98% | 17.4 | 0.0002 |
| CP peak force | 2 (46) | 7.6 | 0.6–14.6 | 2.1 (0.03) | 81% | ||
| CP other | 2 (57) | 37.6 | 24.8–50.5 | 5.7 (<0.00001) | 89 | ||
| BC 1-RM | 2 (68) | 9.9 | 3.1–16.7 | 2.9 (0.004) | 91% | 6.8 | 0.009 |
| BC peak force | 1 (22) | 0.2 | -2.6–3 | 0.1 (0.89) | NA | ||
| LP 1-RM | 4 (122) | 41.1 | 21.1–61.1 | 4 (<0.0001) | 98% | 13 | 0.002 |
| LP peak force | 2 (43) | 33.7 | 6–61.4 | 2.4 (0.02) | 94% | ||
| LP other | 1 (27) | 8.5 | 5.6–11.4 | 5.7 (<0.00001) | NA | ||
| LF 1-RM | 6 (180) | 14.4 | 9.6–19.1 | 6 (<0.00001) | 92% | 28 | <0.00001 |
| LF peak force | 1 (22) | 1.2 | -2.5–4.9 | 0.6 (0.53) | NA | ||
| LF other | 2 (87) | 1.1 | -0.3–2.5 | 1.5 (0.14) | 0% | ||
| LE 1-RM | 4 (127) | 24.1 | 18–30.3 | 7.7 (<0.00001) | 63% | 41.3 | <0.00001 |
| LE peak force | 1 (22) | -0.7 | -7.5–6.1 | 0.2 (0.84) | NA | ||
| LE other | 3 (106) | 3.4 | 0.9–5.9 | 2.6 (0.009) | 0% | ||
Subgroup analyses are presented in random effect model. Panel includes n trials (n participants), Weighted mean difference (WMD), 95% confidence interval (95% CI), Z-score (Z) and significance (p) of exercise vs. control conditions. Statistical heterogeneity (I2). Subgroup differences are tested by the Chi-square (χ2) and significance (p). Not able to calculate (NA)